160
Views
2
CrossRef citations to date
0
Altmetric
Brief Report

Outcomes of Patients with Sarcoma and COVID-19 Infection: A Single Institution Cohort Analysis

ORCID Icon, , , , , , ORCID Icon, , , , & show all
Pages 315-320 | Received 02 Feb 2021, Accepted 12 Mar 2021, Published online: 26 Mar 2021

References

  • Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6.
  • Desai A, Sachdeva S, Parekh T, Desai R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–559. doi:10.1200/GO.20.00097.
  • Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894–901.
  • Albiges L, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C, et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat Cancer. 2020;1(10):965–975. doi:10.1038/s43018-020-00120-5.
  • Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918.
  • Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538–3546.
  • Wise-Draper TM, Desai A, Elkrief A, Rini BI, Flora DB, Bowles DW, et al. LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Ann Oncol. 2020;31:S1201–S1202. doi:10.1016/j.annonc.2020.08.2312.
  • Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–1774. doi:10.1002/cncr.28657.
  • Crago AM, Brennan MF. Principles in management of soft tissue sarcoma. Adv Surg. 2015;49:107–122. doi:10.1016/j.yasu.2015.04.002.
  • Wagner MJ, Amodu LI, Duh MS, Korves C, Solleza F, Manson SC, et al. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer. 2015;15:175. doi:10.1186/s12885-015-1182-4.
  • Grivas P, Warner J, Shyr Y, Shah D, Rubinstein SM, Kuderer NM, et al. LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: the COVID-19 and Cancer Consortium (CCC19). Ann Oncol. 2020;31:S1202–S1203. doi:10.1016/j.annonc.2020.08.2313.
  • National Comprehensive Cancer Network. Soft Tissue Sarcoma (Version 2.2020). 2020 [accessed 2020 Jun 13]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf
  • Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region – case series. N Engl J Med. 2020;382(21):2012–22. doi:10.1056/NEJMoa2004500.
  • Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu C-Y, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov. 2020;10(10):1514–27. doi:10.1158/2159-8290.CD-20-0941.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.